<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005225.pub2" GROUP_ID="NEUROMUSC" ID="156305011315011767" MERGED_FROM="" MODIFIED="2012-11-14 21:31:17 +0000" MODIFIED_BY="Ruth Brassington" REVIEW_NO="095" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.2">
<COVER_SHEET MODIFIED="2012-11-14 21:31:17 +0000" MODIFIED_BY="Ruth Brassington">
<TITLE MODIFIED="2009-12-09 16:47:22 +0000" MODIFIED_BY="Ruth Brassington">Creatine for amyotrophic lateral sclerosis/motor neuron disease</TITLE>
<CONTACT MODIFIED="2012-11-14 21:31:17 +0000" MODIFIED_BY="Ruth Brassington"><PERSON ID="C329FCE982E26AA2008044A2036A3FD6" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Daniel</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Pastula</LAST_NAME><POSITION>Resident Physician</POSITION><EMAIL_1>Daniel.Pastula@ucsfmedctr.org</EMAIL_1><ADDRESS><DEPARTMENT>Neurology</DEPARTMENT><ORGANISATION>UCSF Medical Center</ORGANISATION><ADDRESS_1>UCSF Neurology, Box 0114</ADDRESS_1><ADDRESS_2>505 Parnassus Ave</ADDRESS_2><CITY>San Francisco</CITY><ZIP>94143-0114</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>1-415-476-1489</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-11-14 21:31:17 +0000" MODIFIED_BY="Ruth Brassington"><PERSON ID="C329FCE982E26AA2008044A2036A3FD6" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Daniel</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Pastula</LAST_NAME><POSITION>Resident Physician</POSITION><EMAIL_1>Daniel.Pastula@ucsfmedctr.org</EMAIL_1><ADDRESS><DEPARTMENT>Neurology</DEPARTMENT><ORGANISATION>UCSF Medical Center</ORGANISATION><ADDRESS_1>UCSF Neurology, Box 0114</ADDRESS_1><ADDRESS_2>505 Parnassus Ave</ADDRESS_2><CITY>San Francisco</CITY><ZIP>94143-0114</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>1-415-476-1489</PHONE_1></ADDRESS></PERSON><PERSON ID="15416" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Dan</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Moore</LAST_NAME><POSITION>Biostatistician</POSITION><EMAIL_1>dmoore@biostat.ucsf.edu</EMAIL_1><EMAIL_2>dmoore@cc.ucsf.edu</EMAIL_2><ADDRESS><DEPARTMENT>Research Institute</DEPARTMENT><ORGANISATION>California Pacific Medical Center</ORGANISATION><ADDRESS_1>475 Brannan St Suite 220</ADDRESS_1><CITY>San Francisco</CITY><ZIP>94107</ZIP><REGION>CA</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>00 1 415 600 1567</PHONE_1><FAX_1>00 1 415 600 1725</FAX_1></ADDRESS></PERSON><PERSON ID="CAE8C28182E26AA2014E8D671D792CD3" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Richard</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Bedlack</LAST_NAME><POSITION>Neurologist</POSITION><EMAIL_1>bedla001@mc.duke.edu</EMAIL_1><ADDRESS><DEPARTMENT>Division of Neurology</DEPARTMENT><ORGANISATION>Duke Medical Center</ORGANISATION><ADDRESS_1>Box 3333</ADDRESS_1><CITY>Durham</CITY><ZIP>NC 27707</ZIP><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+ 919 668 2839</PHONE_1><FAX_1>+ 919 668 2901</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-11-14 21:30:16 +0000" MODIFIED_BY="Ruth Brassington">
<UP_TO_DATE>
<DATE DAY="16" MONTH="7" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="16" MONTH="7" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="16" MONTH="7" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="6" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2012-11-08 09:30:04 +0000" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-11-08 09:30:04 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="24" MONTH="8" YEAR="2012"/>
<DESCRIPTION>
<P>Searches updated. No new trials identified</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-09-28 13:40:44 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="8" YEAR="2012"/>
<DESCRIPTION>
<P>Contact details revised</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-11-08 09:52:15 +0000" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-11-08 09:52:15 +0000" MODIFIED_BY="Ruth Brassington">
<DATE DAY="24" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-04-20 14:23:21 +0100" MODIFIED_BY="Ruth Brassington">
<INTERNAL_SOURCES MODIFIED="2010-04-20 14:23:21 +0100" MODIFIED_BY="Ruth Brassington">
<SOURCE MODIFIED="2010-04-20 14:23:21 +0100" MODIFIED_BY="Ruth Brassington">
<NAME>Duke University Medical Center</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Logistical support only. No financial support was received.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2010-03-10 18:44:44 +0000" MODIFIED_BY="[Empty name]">
<NAME>California Pacific Medical Center</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Logistical support only. No financial support was received.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2010-03-10 18:44:02 +0000" MODIFIED_BY="[Empty name]">
<NAME>UCSF Medical Center</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Logistical support only. No financial support was received.</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-11-13 10:41:46 +0000" MODIFIED_BY="Ruth Brassington">
<SUMMARY MODIFIED="2012-11-08 09:39:31 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-12-09 17:19:24 +0000" MODIFIED_BY="Ruth Brassington">Creatine for amyotrophic lateral sclerosis/motor neuron disease</TITLE>
<SUMMARY_BODY MODIFIED="2012-11-08 09:39:31 +0000" MODIFIED_BY="[Empty name]">
<P>Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a progressive neurodegenerative disease that results in widespread paralysis and shortened life. Recently, a naturally-occurring organic acid called creatine has gained attention as a potential therapy for ALS/MND. However, human trials have shown mixed results thus far. Therefore, we systematically reviewed all available clinical trial evidence as of July 2012 to determine if creatine benefits or harms people with ALS/MND. This review included three well-designed clinical trials involving a total of 386 participants receiving either creatine or placebo. Overall, creatine was well-tolerated with no serious side effects. Using various statistical methods, we found that creatine at a dose of 5 to 10 g per day did not improve ALS survival or slow ALS progression in any meaningful way. There was a hint that creatine may slightly worsen breathing ability, but this may have just been misleading statistical variability.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-11-13 10:40:42 +0000" MODIFIED_BY="Ruth Brassington">
<ABS_BACKGROUND MODIFIED="2012-11-08 09:30:14 +0000" MODIFIED_BY="[Empty name]">
<P>Creatine, a naturally-occurring nitrogenous organic acid involved in adenosine triphosphate (ATP) production, has been shown to increase survival in mouse models of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND). Results from human trials, however, have been mixed. Given conflicting results regarding the efficacy of creatine, we conducted a systematic review, which was updated in 2012.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-11-13 10:40:42 +0000" MODIFIED_BY="Ruth Brassington">
<P>To systematically examine the efficacy of creatine efficacy in prolonging ALS survival and in slowing ALS disease progression.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-09-28 13:42:17 +0100" MODIFIED_BY="Ruth Brassington">
<P>We searched the Cochrane Neuromuscular Disease Group Specialized Register (16 July 2012), CENTRAL (2012, issue 7 in <I>the Cochrane Library</I>), MEDLINE (January 1966 to July 2012) and EMBASE (January 1980 to July 2012) for any trial involving creatine in the treatment of ALS. We also contacted experts in the field for any additional studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-11-08 09:30:16 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized trials of treatment with creatine or placebo in patients diagnosed with ALS. Our primary outcome was tracheostomy-free survival time; secondary outcomes were ALS progression as measured by changes in ALS functional rating revised scores (ALSFRS-R) and per cent predicted forced vital capacity (FVC) over time.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-05-09 02:17:26 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently selected studies, assessed risk of bias and extracted data. We obtained and analyzed individual participant data from each study.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-11-08 09:30:23 +0000" MODIFIED_BY="[Empty name]">
<P>We included three trials involving 386 participants randomized to either creatine 5 to 10 g per day or placebo. When we updated the searches in 2012 we found no additional trials. Creatine was reportedly well-tolerated in all three included studies, with no evidence of renal failure or serious adverse events specifically attributable to creatine. Using a pooled log-rank statistical test, we found no statistical difference in survival between the placebo and creatine groups across all three studies (Chi<SUP>2</SUP> = 0.09, P = 0.76). In addition, we found no statistical difference in ALSFRS-R slopes between the two groups across all three studies using a pooled linear mixed-effects model (slope difference of +0.03 ALSFRS-R/month in the creatine group; P = 0.76). Interestingly, there was a trend towards slightly worsened FVC slope in the creatine group (slope difference of -0.63 FVC/month in the creatine group) using a pooled linear mixed-effects model across the two studies which included FVC as an outcome, but this difference was not statistically significant (P = 0.054).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-11-08 09:30:31 +0000" MODIFIED_BY="[Empty name]">
<P>In patients already diagnosed with clinically probable or definite ALS, creatine at doses ranging from 5 to 10 g per day did not have a statistically significant effect on survival, ALSFRS-R progression or percent predicted FVC progression.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-11-13 10:41:18 +0000" MODIFIED_BY="Ruth Brassington">
<BACKGROUND MODIFIED="2012-11-08 09:30:52 +0000" MODIFIED_BY="[Empty name]">
<P>Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), is a progressive neurodegenerative disease that results in widespread paralysis and shortened life. It is thought to be universally fatal, with a median survival of two to five years from symptom onset (<LINK REF="REF-Chancellor-1993" TYPE="REFERENCE">Chancellor 1993</LINK>; <LINK REF="REF-Czaplinski-2006" TYPE="REFERENCE">Czaplinski 2006</LINK>; <LINK REF="REF-Del-Aguila-2003" TYPE="REFERENCE">Del Aguila 2003</LINK>; <LINK REF="REF-Millul-2005" TYPE="REFERENCE">Millul 2005</LINK>; <LINK REF="REF-Pastula-2009" TYPE="REFERENCE">Pastula 2009</LINK>; <LINK REF="REF-Testa-2004" TYPE="REFERENCE">Testa 2004</LINK>). ALS is a rare disease, with an approximate prevalence of 5 per 100,000 and incidence of 2 per 100,000 per year (<LINK REF="REF-Mandrioli-2003" TYPE="REFERENCE">Mandrioli 2003</LINK>; <LINK REF="REF-Sorenson-2002" TYPE="REFERENCE">Sorenson 2002</LINK>; <LINK REF="REF-Worms-2001" TYPE="REFERENCE">Worms 2001</LINK>). About 5% to 10% of ALS cases have a hereditary component (i.e. familial ALS) and the other 90% to 95% of cases have no known family history (i.e. sporadic ALS) (<LINK REF="REF-Li-1988" TYPE="REFERENCE">Li 1988</LINK>; <LINK REF="REF-Rosen-1993" TYPE="REFERENCE">Rosen 1993</LINK>; <LINK REF="REF-Siddique-1995" TYPE="REFERENCE">Siddique 1995</LINK>). The exact cause of ALS is unknown, but theories have suggested that infection, glutamate toxicity, oxidative stress, neuro-inflammation, protein aggregation, mitochondrial dysfunction and cytoskeletal abnormalities may play roles (<LINK REF="REF-Goodall-2006" TYPE="REFERENCE">Goodall 2006</LINK>; <LINK REF="REF-Przedborski--2003" TYPE="REFERENCE">Przedborski 2003</LINK>; <LINK REF="REF-Rowland-2001" TYPE="REFERENCE">Rowland 2001</LINK>).  </P>
<P>Currently, riluzole (a glutamate antagonist and sodium channel blocker) is the only approved disease-modifying medication for ALS, modestly improving survival by approximately two to four months (<LINK REF="REF-Bensimon-1994" TYPE="REFERENCE">Bensimon 1994</LINK>; <LINK REF="REF-Lacomblez-1996" TYPE="REFERENCE">Lacomblez 1996</LINK>). It is fairly expensive (costing approximately US$900 per month) and requires frequent liver function testing (<LINK REF="REF-Sanofi_x002d_Aventis-2006" TYPE="REFERENCE">Sanofi-Aventis 2006</LINK>). Other treatments for ALS are mainly supportive, though there is evidence that percutaneous endoscopic gastrostomy (PEG) tubes, non-invasive ventilatory bi-level positive airway pressure (BIPAP) assistance, and enrolment in a multidisciplinary ALS clinic may improve survival by several months (<LINK REF="REF-Kleopa-1999" TYPE="REFERENCE">Kleopa 1999</LINK>; <LINK REF="REF-Mathus_x002d_Vliegen-1994" TYPE="REFERENCE">Mathus-Vliegen 1994</LINK>; <LINK REF="REF-Mazzini-1995" TYPE="REFERENCE">Mazzini 1995</LINK>; <LINK REF="REF-Miller-2009" TYPE="REFERENCE">Miller 2009</LINK>; <LINK REF="REF-Traynor-2003" TYPE="REFERENCE">Traynor 2003</LINK>). Unfortunately, no treatment to date has been shown to reverse ALS progression or prolong survival by more than several months.</P>
<P>Recently, creatine has been investigated as a possible treatment for ALS. Creatine is a naturally-occurring nitrogenous organic acid found primarily in skeletal muscle that helps produce adenosine triphosphate (ATP) during times of anaerobic metabolism (<LINK REF="REF-Bessman-1985" TYPE="REFERENCE">Bessman 1985</LINK>; <LINK REF="REF-Meyer-1984" TYPE="REFERENCE">Meyer 1984</LINK>). It appears to have antioxidant and neuroprotective properties, and may even enhance mitochondrial function (<LINK REF="REF-Adhihetty-2008" TYPE="REFERENCE">Adhihetty 2008</LINK>; <LINK REF="REF-Lawler-2002" TYPE="REFERENCE">Lawler 2002</LINK>; <LINK REF="REF-Sestili-2006" TYPE="REFERENCE">Sestili 2006</LINK>). Given that oxidative stress and mitochondrial dysfunction may play roles in ALS (<LINK REF="REF-Goodall-2006" TYPE="REFERENCE">Goodall 2006</LINK>; <LINK REF="REF-Przedborski--2003" TYPE="REFERENCE">Przedborski 2003</LINK>; <LINK REF="REF-Rowland-2001" TYPE="REFERENCE">Rowland 2001</LINK>), creatine became an attractive candidate for ALS researchers. Shortly after creatine was shown to prolong survival in animal models of ALS (<LINK REF="REF-Klivenyi-1999" TYPE="REFERENCE">Klivenyi 1999</LINK>), clinical trials in human subjects were commenced. </P>
<P>The first studies on creatine showed promise in slowing ALS progression. In a small, unpublished, randomized, placebo-controlled pilot study of 20 ALS patients, creatine was associated with a significant benefit in upper extremity muscle strength compared to placebo at one, two and three weeks and at nine months (<LINK REF="STD-Rosenfeld-2001" TYPE="STUDY">Rosenfeld 2001</LINK>). In addition, a non-blinded study of 28 ALS patients showed that creatine treatment was associated with improved muscle function at seven days, compared to pre-treatment baseline (<LINK REF="REF-Mazzini-2001" TYPE="REFERENCE">Mazzini 2001</LINK>).</P>
<P>However, later studies produced conflicting results. For instance, a non-blinded study with 27 participants was unable to show any benefit on pulmonary function assessed after one, two, three or four months (<LINK REF="REF-Drory-2002" TYPE="REFERENCE">Drory 2002</LINK>). In addition, a randomized, double-blind, placebo-controlled study with 175 participants was unable to show any benefit of creatine on survival or functional measures at time points between one and 16 months (<LINK REF="STD-Groeneveld-2003" TYPE="STUDY">Groeneveld 2003</LINK>). Furthermore, a double-blind placebo controlled study with 104 participants was similarly unable to show any benefit of creatine on muscle strength, function or electrophysiological outcomes (<LINK REF="STD-Shefner-2004" TYPE="STUDY">Shefner 2004</LINK>).</P>
<P>Given these conflicting results and the promise that creatine may have in the treatment in ALS, we believed that a systematic review regarding its efficacy was warranted. We ran updated searches in 2012.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-12-09 16:47:22 +0000" MODIFIED_BY="Ruth Brassington">
<P>The objective of this review is to systematically examine creatine's efficacy in prolonging ALS survival and in slowing ALS disease progression.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-11-13 10:40:57 +0000" MODIFIED_BY="Ruth Brassington">
<SELECTION_CRITERIA MODIFIED="2012-11-08 09:31:00 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-11-08 09:30:54 +0000" MODIFIED_BY="[Empty name]">
<P>We considered only randomized controlled trials (RCTs) or quasi-RCTs in which creatine was tested as a potential treatment for ALS. We only included trials in which original individual participant data and study methods were available.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-05-07 11:20:23 +0100" MODIFIED_BY="Ruth Brassington">
<P>We considered any creatine trial in which participants were diagnosed with ALS in any state, at any stage. We did not place any restrictions on age, gender or co-morbidities.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-12-09 16:47:22 +0000" MODIFIED_BY="Ruth Brassington">
<P>We considered any creatine trial in which creatine had been compared to placebo in any form, frequency, dosage, or in combination with other products. We did not place a minimum or maximum limit on treatment duration.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-11-08 09:31:00 +0000" MODIFIED_BY="Ruth Brassington">
<P>Our primary outcome of interest was tracheostomy-free survival time. Our secondary outcome of interest was ALS disease progression (by changes in either ALS functional rating revised scores (ALSFRS-R) (<LINK REF="REF-Brooks-2000" TYPE="REFERENCE">Brooks 2000</LINK>; <LINK REF="REF-Gordon-2004" TYPE="REFERENCE">Gordon 2004</LINK>) or per cent predicted forced vital capacity (FVC)).<BR/>
</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-02-27 01:21:50 +0000" MODIFIED_BY="[Empty name]">
<P>1) Tracheostomy-free survival time.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-11-08 09:31:00 +0000" MODIFIED_BY="Ruth Brassington">
<P>2) Change in ALSFRS-R over time.</P>
<P>3) Change in per cent predicted FVC over time.</P>
<SUBSECTION>
<HEADING LEVEL="5">Follow up</HEADING>
<P>There were no restrictions based on the length of follow up.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-11-13 10:40:57 +0000" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;&lt;span modified=&quot;2011-09-27 15:35:40 +0100&quot; modified_by=&quot;Angela A Gunn&quot; class=&quot;inserted&quot;&gt;The number of papers found by the new, current strategies are&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2011-09-27 15:35:40 +0100&quot; modified_by=&quot;Angela A Gunn&quot; class=&quot;inserted&quot;&gt;MEDLINE - 7&lt;/span&gt;1&lt;span modified=&quot;2011-09-27 15:35:40 +0100&quot; modified_by=&quot;Angela A Gunn&quot; class=&quot;inserted&quot;&gt; (&lt;/span&gt;16&lt;span modified=&quot;2011-09-27 15:35:40 +0100&quot; modified_by=&quot;Angela A Gunn&quot; class=&quot;inserted&quot;&gt; new papers)&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2011-09-27 15:35:40 +0100&quot; modified_by=&quot;Angela A Gunn&quot; class=&quot;inserted&quot;&gt;EMBASE - 3&lt;/span&gt;5&lt;span modified=&quot;2011-09-27 15:35:40 +0100&quot; modified_by=&quot;Angela A Gunn&quot; class=&quot;inserted&quot;&gt; (&lt;/span&gt;10&lt;span modified=&quot;2011-09-27 15:35:40 +0100&quot; modified_by=&quot;Angela A Gunn&quot; class=&quot;inserted&quot;&gt; new papers)&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2011-09-27 15:35:40 +0100&quot; modified_by=&quot;Angela A Gunn&quot; class=&quot;inserted&quot;&gt;NMD REGISTER - 1&lt;/span&gt;4 &lt;span modified=&quot;2011-09-27 15:35:40 +0100&quot; modified_by=&quot;Angela A Gunn&quot; class=&quot;inserted&quot;&gt;(&lt;/span&gt;2&lt;span modified=&quot;2011-09-27 15:35:40 +0100&quot; modified_by=&quot;Angela A Gunn&quot; class=&quot;inserted&quot;&gt; new papers)&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2011-09-27 15:35:40 +0100&quot; modified_by=&quot;Angela A Gunn&quot; class=&quot;inserted&quot;&gt;CENTRAL - 1&lt;/span&gt;&lt;span modified=&quot;2011-09-27 15:36:00 +0100&quot; modified_by=&quot;Angela A Gunn&quot; class=&quot;inserted&quot;&gt;9&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2011-09-27 15:35:40 +0100&quot; modified_by=&quot;Angela A Gunn&quot; class=&quot;inserted&quot;&gt;The NMD Group is now following the Cochrane policy of giving the total number of references found by each database, the number of references after deduplication, the number of references selected for further review and the number meeting the inclusion criteria for the review.&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2011-09-27 15:35:40 +0100&quot; modified_by=&quot;Angela A Gunn&quot; class=&quot;inserted&quot;&gt;The numbers given above are total references retrieved (and in brackets the references retrieved since the last published review).&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-11-13 10:40:57 +0000" NOTES_MODIFIED_BY="Ruth Brassington">
<P>We searched the Cochrane Neuromuscular Disease Group Specialized Register (16 July 2012), CENTRAL (2012, issue 7 in <I>the Cochrane Library</I>), MEDLINE (January 1966 to July 2012) and EMBASE (January 1980 to July 2012), as well as abstract booklets of the annual ALS/MND symposia. We used Science Citation Index to find studies that had cited the identified trials. We did not use a language restriction in the searches for trials.<BR/>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2012-11-13 10:40:57 +0000" MODIFIED_BY="Ruth Brassington">
<P>The detailed search strategies are in the appendices: <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> (MEDLINE), <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> (EMBASE) and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> (CENTRAL).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-12-26 17:59:40 +0000" MODIFIED_BY="[Empty name]">
<P>We reviewed the bibliographies of included and ongoing trials, and contacted authors and known experts in the field to identify additional published and unpublished studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-11-08 09:31:25 +0000" MODIFIED_BY="Ruth Brassington">
<P>We obtained original raw data for each individual participant in each included study from the trials' authors. We then combined all original data into one data set, which facilitated statistical analyses. The data were then double-checked by our statistician to ensure accuracy.</P>
<STUDY_SELECTION MODIFIED="2010-05-07 11:21:01 +0100" MODIFIED_BY="Ruth Brassington">
<P>Two review authors independently assessed and reviewed the titles and abstracts of all reports identified by both electronic and manual searches. We obtained full copies of potentially relevant trials and assessed them according to the above review criteria. We initially reviewed all trials and categorized them as either 'exclude', 'unclear', or 'include'. We excluded papers identified by all authors as 'exclude' from further consideration. Papers identified as 'unclear' or 'include' by any author underwent a second review. We were able to resolve all disagreements through discussion, and eventually reached a consensus on which papers to include based on the above inclusion criteria. During this process, we were not blinded to the trial authors, institutions or trial results.</P>
</STUDY_SELECTION>
<QUALITY_ASSESSMENT MODIFIED="2012-11-08 09:31:25 +0000" MODIFIED_BY="Ruth Brassington">
<P>Two authors independently assessed the risk of bias in each included study according to the <I>Cochrane</I> <I>Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>), evaluating six specific domains: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and 'other issues'. We assessed each study as at 'High risk of bias', 'Low risk of bias' or 'Unclear risk of bias' in each domain. We placed particular emphasis on allocation concealment, similar baseline characteristics after randomization, intention-to-treat analysis and explicit outcome criteria.  </P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-05-11 14:19:54 +0100" MODIFIED_BY="Ruth Brassington">
<P>Given all outcome endpoints used in all studies, we judged that pooling survival data, ALSFRS-R data and FVC data would be reasonable as these were relatively standardized measurements largely free of inter- and intra-rater variability. Maximal voluntary isometric contraction (MVIC) arm strength, on the other hand, was not included in our synthesis because it involved measuring a differing number of arm muscles depending on the study and would be hard to synthesize across studies. No other endpoints were used across more than one trial.  </P>
<P>For survival data synthesis, we used individual participant data to calculate survival in both creatine and placebo groups for each study, and then attempted to pool these results. We also fitted a Cox proportional hazards model (<LINK REF="REF-Cox-1972" TYPE="REFERENCE">Cox 1972</LINK>) to the pooled data, and used a log-rank statistic to test for differences in survival between the creatine and placebo groups. </P>
<P>For ALSFRS data synthesis, two of the included studies (<LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK> and <LINK REF="STD-Shefner-2004" TYPE="STUDY">Shefner 2004</LINK>) used ALSFRS-R while the third study (<LINK REF="STD-Groeneveld-2003" TYPE="STUDY">Groeneveld 2003</LINK>) used the older ALSFRS (<LINK REF="REF-Cedarbaum-1999" TYPE="REFERENCE">Cedarbaum 1999</LINK>). Thus, it was necessary to convert the older ALSFRS to ALSFRS-R so that data could be pooled across studies.</P>
<P>We used data from the Shefner trial to define a linear equation to convert ALSFRS to ALSFRS-R since this data set included responses to the single respiratory question of the ALSFRS and to the three respiratory questions of the ALSFRS-R. This allowed us to convert ALSFRS scores from the <LINK REF="STD-Groeneveld-2003" TYPE="STUDY">Groeneveld 2003</LINK> study to the same scale used by the other two studies, ALSFRS-R (<LINK REF="STD-Shefner-2004" TYPE="STUDY">Shefner 2004</LINK> and <LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK>).</P>
<P>The conversion equation used is:</P>
<P>ALSFRS-R = 3.0 + 1.13*ALSFRS</P>
<P>We assumed that ALSFRS-R declined linearly over time (<LINK REF="REF-Traynor-2004" TYPE="REFERENCE">Traynor 2004</LINK>). We fitted a linear mixed-effects (LME) model to the pooled data from all three studies to test for a creatine treatment effect on ALSFRS-R progression. In this LME model, we included fixed-effect terms for intercept (starting value), slope (rate of decline over time) and differences in slope between the creatine and placebo groups. We included random-effects terms for intercept and slope, which allowed for patient-to-patient differences in slope and intercept, and an additional random-effect for each participant's deviation from the linear fit. We also added a fixed-effect term to test whether treatment effects on ALSFRS-R progression differed by trial site.</P>
<P>For FVC data synthesis, we assumed that FVC declined linearly over time (<LINK REF="REF-Traynor-2004" TYPE="REFERENCE">Traynor 2004</LINK>), and we fitted a linear mixed-effects model to test for a creatine treatment effect on FVC score progression. In this LME model, we included fixed-effect terms for intercept (starting value), slope (rate of decline over time) and differences in slope between the creatine and placebo groups. We included random-effects terms for intercept and slope, which allowed for patient-to-patient differences in slope and intercept, and an additional random-effect for each participant's deviation from the linear fit. We also added a fixed-effect term to test whether treatment effects on FVC progression differed by trial site. </P>
<P>We used Stata version 10.1 for Macintosh to analyze survival data and to fit a Cox proportional hazard model to the data. We used the R statistical package (version 2.8.0) program <I>nlme</I> to fit our LME models to the combined data. We summarized our results in a summary of results section and a 'Summary of findings' table.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-11-13 10:41:18 +0000" MODIFIED_BY="Ruth Brassington">
<STUDY_DESCRIPTION MODIFIED="2012-11-13 10:41:18 +0000" MODIFIED_BY="Ruth Brassington">
<SEARCH_RESULTS MODIFIED="2012-11-13 10:41:18 +0000" MODIFIED_BY="Ruth Brassington">
<P>The electronic and manual search strategies described above returned a total of 299 manuscripts or abstracts of potential interest in total for the original review and subsequent update. (The number of papers found by the new, current strategies are: MEDLINE 71 (16 new papers); EMBASE 35 (10 new papers); NMD register 14 (2 new papers); and CENTRAL 19.)</P>
<P>Discussions with experts in the field did not reveal any more studies of possible interest. Two of our review authors independently reviewed each of the 299 manuscripts/abstracts according to the study selection criteria described above. Only three manuscripts (<LINK REF="STD-Groeneveld-2003" TYPE="STUDY">Groeneveld 2003</LINK>; <LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK>; <LINK REF="STD-Shefner-2004" TYPE="STUDY">Shefner 2004</LINK>) met the study selection criteria. The other 296 were excluded by both reviewing authors independently. One excluded study almost met inclusion criteria (<LINK REF="STD-Rosenfeld-2001" TYPE="STUDY">Rosenfeld 2001</LINK>); however, the original participant data and study methods for this small, unpublished, pilot study were not available.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-11-08 09:31:41 +0000" MODIFIED_BY="Ruth Brassington">
<P>Only three studies were included in our systematic review: <LINK REF="STD-Groeneveld-2003" TYPE="STUDY">Groeneveld 2003</LINK>; <LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK>; <LINK REF="STD-Shefner-2004" TYPE="STUDY">Shefner 2004</LINK>. All three were included by both reviewing authors (DMP and RSB) independently.</P>
<P>In <LINK REF="STD-Groeneveld-2003" TYPE="STUDY">Groeneveld 2003</LINK>, 175 ALS patients were randomized in a 1:1 fashion to receive either 10 g per day of creatine monohydrate or placebo. ALS patients who were older than 75 years of age, had an FVC less than 60%, already required ventilation, had ALS longer than five years, or had renal dysfunction were excluded from the study. Outcomes measured included tracheostomy-free survival, ALSFRS scores, FVC, maximum voluntary isometric contraction (MVIC) arm strength, and SF-36 quality of life scores. At both 12 and 16 months, there was no statistical difference in cumulative survival probability between the two groups (0.70 in the creatine group versus 0.68 in the placebo group at 12 months; 0.52 in the creatine group versus 0.47 in the placebo group at 16 months). In addition, the adjusted hazard ratio (HR) failed to show statistical significance in survival between the two groups (HR = 0.78; 95% CI 0.47 to 1.48, creatine group relative to placebo group). There were also no statistical differences between the two groups in regards to ALSFRS score decline (P = 0.30), FVC decline (P = 0.12), MVIC arm strength decline (P = 0.37) or SF-36 quality of life score decline (P = 0.52). Maximum follow up was 6.3 years. More details can be found in <LINK REF="STD-Groeneveld-2003" TYPE="STUDY">Groeneveld 2003</LINK>.</P>
<P>In <LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK>, 107 ALS patients were randomized in a 1:1 fashion to receive either 5 g per day of creatine monohydrate or placebo. ALS patients who were older than 80 years of age, already required ventilation, had ALS longer than five years, had severely weakened upper extremity muscles, or had renal dysfunction were excluded from the study. Outcomes measured included differences in tracheostomy-free survival, ALSFRS-R, FVCs, MVIC arm strength, muscle fatigability and SF-12 quality of life scores. At nine months there were two deaths in the creatine group versus six deaths in the placebo group, which was not considered statistically significant by the trial authors (no P value or HR was reported in the manuscript). There was also no statistical difference between the two groups in regards to ALSFRS-R score decline (P value not reported), FVC decline (P = 0.30), MVIC arm strength decline (P = 0.35), muscle fatiguability (P value not reported) or SF-12 quality of life score decline (P = 0.70). Maximum follow up was six months. More details can be found in <LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK>.</P>
<P>In <LINK REF="STD-Shefner-2004" TYPE="STUDY">Shefner 2004</LINK>, 104 ALS patients were randomized in a 1:1 fashion to receive either creatine monohydrate 5 g per day or placebo for the study duration of six months. ALS patients who were older than 80 years of age, had an FVC less than 50%, already required ventilation, had ALS longer than five years, or had severely weakened upper extremity muscles were excluded from the study. Outcomes measured included differences in tracheostomy-free survival, ALSFRS-R scores, MVIC arm strength, MVIC grip strength and Motor Unit Number Estimation (MUNE) scores. At six months there were two dead in the creatine group and six dead in the placebo group, which was not considered statistically significant (P = 0.21). Furthermore, there was no statistical significance between the two groups in regards to ALSFRS-R score decline (P = 0.85), MVIC arm strength score decline (P = 0.29), MVIC grip strength score decline (P = 0.20) and Motor Unit Number Estimation (MUNE) score decline (P = 0.69). Maximum follow up was 12 months. More details can be found in <LINK REF="STD-Shefner-2004" TYPE="STUDY">Shefner 2004</LINK>.</P>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-05-07 11:23:20 +0100" MODIFIED_BY="Ruth Brassington">
<P>Both the section entitled <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> summarize the review authors' judgements of methodological quality for the included studies. All three studies were double-blinded, placebo-controlled, randomized, analyzed with an intention-to-treat method and reported all stated outcomes.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-11-08 09:31:46 +0000" MODIFIED_BY="Ruth Brassington">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome: tracheostomy-free survival time</HEADING>
<P>Using individual participant data from all three studies we constructed Kaplan-Meier curves for the first year of follow up (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) and calculated log-rank tests to compare survival in creatine and placebo treatment groups. We found significant differences in survival of participants from different studies, with Groenenveld study participants having worse survival than those in the other two studies (P = 0.001 based on a Wilcoxon-Breslow-Gehan test for survival equality). Therefore, it was inappropriate to estimate pooled six-month survival data across all three studies. Also, we found that the HR for creatine over time was non-proportional after fitting a Cox proportional hazards model, stratified by study, to the pooled data; thus an overall HR for creatine could not be appropriately estimated (the finding of non-proportional hazards could be due to a lack of deaths beyond 4.4 months in the <LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK> and <LINK REF="STD-Shefner-2004" TYPE="STUDY">Shefner 2004</LINK> studies). However, we could compare survival using the log-rank test since it does not assume proportional hazards. Results from this test are summarized in Table 1, and show no significant effect of creatine on survival (log rank test, Chi<SUP>2</SUP> = 0.09, P = 0.76).<BR/>
<BR/>
<B>Table 1: Survival analysis </B>
</P>
<TABLE COLS="5" ROWS="6">
<TR>
<TH>
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>6-month survival</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Log-rank test</P>
</TH>
</TR>
<TR>
<TH>
<P>Study</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Placebo</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Creatine</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Chi<SUP>2</SUP>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>P value</P>
</TH>
</TR>
<TR>
<TH>
<P>
<LINK REF="STD-Groeneveld-2003" TYPE="STUDY">Groeneveld 2003</LINK>
</P>
</TH>
<TD ALIGN="CENTER">
<P>86%</P>
</TD>
<TD ALIGN="CENTER">
<P>83%</P>
</TD>
<TD ALIGN="CENTER">
<P>0.13</P>
</TD>
<TD ALIGN="CENTER">
<P>0.72</P>
</TD>
</TR>
<TR>
<TH>
<P>
<LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK>
</P>
</TH>
<TD ALIGN="CENTER">
<P>96%</P>
</TD>
<TD ALIGN="CENTER">
<P>96%</P>
</TD>
<TD ALIGN="CENTER">
<P>1.76</P>
</TD>
<TD ALIGN="CENTER">
<P>0.18</P>
</TD>
</TR>
<TR>
<TH>
<P>
<LINK REF="STD-Shefner-2004" TYPE="STUDY">Shefner 2004</LINK>
</P>
</TH>
<TD ALIGN="CENTER">
<P>91%</P>
</TD>
<TD ALIGN="CENTER">
<P>96%</P>
</TD>
<TD ALIGN="CENTER">
<P>1.60</P>
</TD>
<TD ALIGN="CENTER">
<P>0.21</P>
</TD>
</TR>
<TR>
<TH>
<P>Pooled</P>
</TH>
<TD ALIGN="CENTER">
<P>NA<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>NA<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>0.09</P>
</TD>
<TD ALIGN="CENTER">
<P>0.76</P>
</TD>
</TR>
</TABLE>
<P>
<SUP>1</SUP>Pooling 6-month survival over the three studies is not appropriate due to significant differences among the groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcome: change in ALS functional rating revised scores (ALSFRS-R) over time</HEADING>
<P>We fitted a linear regression model to each participant's ALSFRS-R, with individual fit results summarized in Table 2A.  Looking at the pooled individual fit linear regression results, we see that the difference in slope between the placebo and creatine groups across all three studies is 0.09 (-1.10 for placebo versus -1.01 for creatine).</P>
<P>
<B>Table 2A: ALSFRS-R individual fit linear regression model </B>
<BR/>
</P>
<TABLE COLS="6" ROWS="14">
<TR>
<TH COLSPAN="2" ROWSPAN="2">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Initial scores</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="BOTTOM">
<P>Slopes</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Placebo</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Creatine</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Placebo</P>
</TH>
<TH ALIGN="CENTER" VALIGN="BOTTOM">
<P>Creatine</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="3">
<P>
<LINK REF="STD-Groeneveld-2003" TYPE="STUDY">Groeneveld 2003</LINK>
</P>
</TH>
<TH>
<P>Sample size</P>
</TH>
<TD ALIGN="CENTER">
<P>87</P>
</TD>
<TD ALIGN="CENTER">
<P>88</P>
</TD>
<TD ALIGN="CENTER">
<P>85</P>
</TD>
<TD ALIGN="CENTER">
<P>83</P>
</TD>
</TR>
<TR>
<TH>
<P>Mean</P>
</TH>
<TD ALIGN="CENTER">
<P>37.7</P>
</TD>
<TD ALIGN="CENTER">
<P>37.2</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.07</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.99</P>
</TD>
</TR>
<TR>
<TH>
<P>Standard deviation</P>
</TH>
<TD ALIGN="CENTER">
<P>5.5</P>
</TD>
<TD ALIGN="CENTER">
<P>6.0</P>
</TD>
<TD ALIGN="CENTER">
<P>1.27</P>
</TD>
<TD ALIGN="CENTER">
<P>1.23</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3">
<P>
<LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK>
</P>
</TH>
<TH>
<P>Sample size</P>
</TH>
<TD ALIGN="CENTER">
<P>54</P>
</TD>
<TD ALIGN="CENTER">
<P>53</P>
</TD>
<TD ALIGN="CENTER">
<P>54</P>
</TD>
<TD ALIGN="CENTER">
<P>53</P>
</TD>
</TR>
<TR>
<TH>
<P>Mean</P>
</TH>
<TD ALIGN="CENTER">
<P>36.4</P>
</TD>
<TD ALIGN="CENTER">
<P>35.9</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.16</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.09</P>
</TD>
</TR>
<TR>
<TH>
<P>Standard deviation</P>
</TH>
<TD ALIGN="CENTER">
<P>6.7</P>
</TD>
<TD ALIGN="CENTER">
<P>5.5</P>
</TD>
<TD ALIGN="CENTER">
<P>1.34</P>
</TD>
<TD ALIGN="CENTER">
<P>1.00</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3">
<P>
<LINK REF="STD-Shefner-2004" TYPE="STUDY">Shefner 2004</LINK>
</P>
</TH>
<TH>
<P>Sample size</P>
</TH>
<TD ALIGN="CENTER">
<P>48</P>
</TD>
<TD ALIGN="CENTER">
<P>46</P>
</TD>
<TD ALIGN="CENTER">
<P>45</P>
</TD>
<TD ALIGN="CENTER">
<P>45</P>
</TD>
</TR>
<TR>
<TH>
<P>Mean</P>
</TH>
<TD ALIGN="CENTER">
<P>37.4</P>
</TD>
<TD ALIGN="CENTER">
<P>38.3</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.07</P>
</TD>
<TD ALIGN="CENTER">
<P>-0.93</P>
</TD>
</TR>
<TR>
<TH>
<P>Standard deviation</P>
</TH>
<TD ALIGN="CENTER">
<P>5.9</P>
</TD>
<TD ALIGN="CENTER">
<P>5.3</P>
</TD>
<TD ALIGN="CENTER">
<P>1.16</P>
</TD>
<TD ALIGN="CENTER">
<P>1.14</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3">
<P>Pooled</P>
</TH>
<TH>
<P>Sample size</P>
</TH>
<TD ALIGN="CENTER">
<P>189</P>
</TD>
<TD ALIGN="CENTER">
<P>187</P>
</TD>
<TD ALIGN="CENTER">
<P>184</P>
</TD>
<TD ALIGN="CENTER">
<P>181</P>
</TD>
</TR>
<TR>
<TH>
<P>Mean</P>
</TH>
<TD ALIGN="CENTER">
<P>37.3</P>
</TD>
<TD ALIGN="CENTER">
<P>37.1</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.10</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.01</P>
</TD>
</TR>
<TR>
<TH>
<P>Standard deviation</P>
</TH>
<TD ALIGN="CENTER">
<P>6.0</P>
</TD>
<TD ALIGN="CENTER">
<P>5.7</P>
</TD>
<TD ALIGN="CENTER">
<P>1.26</P>
</TD>
<TD ALIGN="CENTER">
<P>1.14</P>
</TD>
</TR>
</TABLE>
<P>A graphical depiction of the data in Table 2A can be seen in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, where we plotted the individual fit ALSFRS-R slopes estimates by treatment and by study.<BR/>
</P>
<P>From the individual fit linear regression model data, there does not seem to be much difference in ALSFRS-R slopes between the placebo and creatine groups. However, since we had all measurements on each participant it was more efficient to fit a linear mixed-effects model to the pooled data than to compare the slope estimates from each fit separately. The results of the mixed-effects fit are summarized in Table 2B.</P>
<P>
<B>Table 2B: ALSFRS-R linear mixed-effects model</B>
<BR/>
</P>
<TABLE COLS="7" ROWS="9">
<TR>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Source</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Coefficients</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Standard error</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Z-Score</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>P value</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>95% confidence</P>
<P>
<B>interval</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Month</P>
</TH>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>-1.01</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.07</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>-14.69</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>&lt;0.01</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>-1.15</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>-0.88</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Treatment</P>
</TH>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>-0.06</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.62</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>-0.10</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.92</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>-1.28</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.15</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Month x treatment</P>
</TH>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.03</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.10</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.31</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.76</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>-0.16</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.22</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="MIDDLE">
<P>Intercept</P>
</TH>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>37.46</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.44</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>85.94</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>&lt;0.01</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>36.60</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>38.31</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT">
<P>Random-effects parameters</P>
</TH>
<TH ALIGN="CENTER">
<P>Estimate</P>
</TH>
<TH ALIGN="CENTER">
<P>Standard error</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>95% confidence</P>
<P>interval</P>
</TH>
<TH COLSPAN="2" ROWSPAN="4">
<P/>
</TH>
</TR>
<TR>
<TH>
<P>SD (month)</P>
</TH>
<TD ALIGN="CENTER">
<P>0.80</P>
</TD>
<TD ALIGN="CENTER">
<P>0.04</P>
</TD>
<TD ALIGN="CENTER">
<P>0.72</P>
</TD>
<TD ALIGN="CENTER">
<P>0.89</P>
</TD>
</TR>
<TR>
<TH>
<P>SD (intercept)</P>
</TH>
<TD ALIGN="CENTER">
<P>5.87</P>
</TD>
<TD ALIGN="CENTER">
<P>0.22</P>
</TD>
<TD ALIGN="CENTER">
<P>5.44</P>
</TD>
<TD ALIGN="CENTER">
<P>6.32</P>
</TD>
</TR>
<TR>
<TH>
<P>SD (residual)</P>
</TH>
<TD ALIGN="CENTER">
<P>1.85</P>
</TD>
<TD ALIGN="CENTER">
<P>0.04</P>
</TD>
<TD ALIGN="CENTER">
<P>1.77</P>
</TD>
<TD ALIGN="CENTER">
<P>1.92</P>
</TD>
</TR>
</TABLE>
<P>In our linear mixed-effects model, the only significant fixed-effects across studies were the intercept (initial mean ALSFRS-R) and slope (change in ALSFRS-R per month). In our initial analysis, our model included terms for interactions between study and month and treatment to allow for different slopes among the three studies. None of the interaction terms were significant, so we re-ran the analysis using only month and treatment to test whether slopes, with pooled estimates over the three studies, differed by treatment. The results are summarized in Table 2B. The test for a treatment effect (month x treatment in Table 2B) was not significant (P = 0.76) indicating that treatment did not affect rate of decline of ALSFRS-R over time.  </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcome: change in forced vital capacity (FVC) over time</HEADING>
<P>We fitted a linear regression model to each participant's FVC scores, with individual fit results summarized in Table 3A. Since the <LINK REF="STD-Shefner-2004" TYPE="STUDY">Shefner 2004</LINK> study did not record FVC at times other than study enrolment, only two studies were included in the FVC analysis. Looking at the pooled individual fit linear regression results, we see that the difference in slope between the placebo and creatine groups across two studies is -0.33 (-2.70 for placebo versus -3.03 for creatine).</P>
<P>
<B>Table 3A: FVC individual fit linear regression model </B>
<BR/>
</P>
<TABLE COLS="6" ROWS="11">
<TR>
<TH ROWSPAN="2">
<P>Study</P>
</TH>
<TH ROWSPAN="2">
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>Initial scores</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>Slopes</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER">
<P>Placebo</P>
</TH>
<TH ALIGN="CENTER">
<P>Creatine</P>
</TH>
<TH ALIGN="CENTER">
<P>Placebo</P>
</TH>
<TH ALIGN="CENTER">
<P>Creatine</P>
</TH>
</TR>
<TR>
<TH ROWSPAN="3">
<P>
<LINK REF="STD-Groeneveld-2003" TYPE="STUDY">Groeneveld 2003</LINK>
</P>
</TH>
<TH>
<P>Sample size</P>
</TH>
<TD ALIGN="CENTER">
<P>87</P>
</TD>
<TD ALIGN="CENTER">
<P>88</P>
</TD>
<TD ALIGN="CENTER">
<P>85</P>
</TD>
<TD ALIGN="CENTER">
<P>83</P>
</TD>
</TR>
<TR>
<TH>
<P>Mean</P>
</TH>
<TD ALIGN="CENTER">
<P>89.1</P>
</TD>
<TD ALIGN="CENTER">
<P>90.7</P>
</TD>
<TD ALIGN="CENTER">
<P>-3.18</P>
</TD>
<TD ALIGN="CENTER">
<P>-3.42</P>
</TD>
</TR>
<TR>
<TH>
<P>Standard deviation</P>
</TH>
<TD ALIGN="CENTER">
<P>18.4</P>
</TD>
<TD ALIGN="CENTER">
<P>18.7</P>
</TD>
<TD ALIGN="CENTER">
<P>5.62</P>
</TD>
<TD ALIGN="CENTER">
<P>4.55</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3">
<P>
<LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK>
</P>
</TH>
<TH>
<P>Sample size</P>
</TH>
<TD ALIGN="CENTER">
<P>54</P>
</TD>
<TD ALIGN="CENTER">
<P>53</P>
</TD>
<TD ALIGN="CENTER">
<P>54</P>
</TD>
<TD ALIGN="CENTER">
<P>53</P>
</TD>
</TR>
<TR>
<TH>
<P>Mean</P>
</TH>
<TD ALIGN="CENTER">
<P>72.8</P>
</TD>
<TD ALIGN="CENTER">
<P>76.2</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.96</P>
</TD>
<TD ALIGN="CENTER">
<P>-2.40</P>
</TD>
</TR>
<TR>
<TH>
<P>Standard deviation</P>
</TH>
<TD ALIGN="CENTER">
<P>23.7</P>
</TD>
<TD ALIGN="CENTER">
<P>17.9</P>
</TD>
<TD ALIGN="CENTER">
<P>2.05</P>
</TD>
<TD ALIGN="CENTER">
<P>4.81</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3">
<P>Pooled</P>
</TH>
<TH>
<P>Sample size</P>
</TH>
<TD ALIGN="CENTER">
<P>141</P>
</TD>
<TD ALIGN="CENTER">
<P>141</P>
</TD>
<TD ALIGN="CENTER">
<P>139</P>
</TD>
<TD ALIGN="CENTER">
<P>136</P>
</TD>
</TR>
<TR>
<TH>
<P>Mean</P>
</TH>
<TD ALIGN="CENTER">
<P>84.9</P>
</TD>
<TD ALIGN="CENTER">
<P>85.2</P>
</TD>
<TD ALIGN="CENTER">
<P>-2.70</P>
</TD>
<TD ALIGN="CENTER">
<P>-3.03</P>
</TD>
</TR>
<TR>
<TH>
<P>Standard deviation</P>
</TH>
<TD ALIGN="CENTER">
<P>21.2</P>
</TD>
<TD ALIGN="CENTER">
<P>19.6</P>
</TD>
<TD ALIGN="CENTER">
<P>4.60</P>
</TD>
<TD ALIGN="CENTER">
<P>4.66</P>
</TD>
</TR>
</TABLE>
<P>A graphical depiction of the data in Table 3A can be seen in <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK> below, where we plotted the individual fit FVC slopes estimates by treatment and by study.</P>
<P>From the individual fit linear regression model, there is a slight difference in FVC slopes between the placebo and creatine groups (-2.70 for placebo versus -3.03 for creatine). However, as explained above, it is more efficient to pool the data and then fit a single mixed-effects model to the pooled data than to compare individual fit estimates. The results of fitting the model to the FVC data are summarized in Table 3B.</P>
<P>
<B>Table 3B: FVC linear mixed-effects model</B>
<BR/>
</P>
<TABLE COLS="7" ROWS="10">
<TR>
<TH>
<P>Source</P>
</TH>
<TH ALIGN="CENTER">
<P>Coefficient</P>
</TH>
<TH ALIGN="CENTER">
<P>Standard error</P>
</TH>
<TH ALIGN="CENTER">
<P>Z-score</P>
</TH>
<TH ALIGN="CENTER">
<P>P value</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>95% confidence</P>
<P>
<B>interval</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P>Study</P>
</TH>
<TD ALIGN="CENTER">
<P>-12.32</P>
</TD>
<TD ALIGN="CENTER">
<P>2.45</P>
</TD>
<TD ALIGN="CENTER">
<P>-5.02</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 0.01</P>
</TD>
<TD ALIGN="CENTER">
<P>-17.13</P>
</TD>
<TD ALIGN="CENTER">
<P>-7.51</P>
</TD>
</TR>
<TR>
<TH>
<P>Month</P>
</TH>
<TD ALIGN="CENTER">
<P>-2.12</P>
</TD>
<TD ALIGN="CENTER">
<P>0.23</P>
</TD>
<TD ALIGN="CENTER">
<P>-9.12</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 0.01</P>
</TD>
<TD ALIGN="CENTER">
<P>-2.57</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.66</P>
</TD>
</TR>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TD ALIGN="CENTER">
<P>1.02</P>
</TD>
<TD ALIGN="CENTER">
<P>2.40</P>
</TD>
<TD ALIGN="CENTER">
<P>0.42</P>
</TD>
<TD ALIGN="CENTER">
<P>0.67</P>
</TD>
<TD ALIGN="CENTER">
<P>-3.68</P>
</TD>
<TD ALIGN="CENTER">
<P>5.71</P>
</TD>
</TR>
<TR>
<TH>
<P>Month x treatment</P>
</TH>
<TD ALIGN="CENTER">
<P>-0.63</P>
</TD>
<TD ALIGN="CENTER">
<P>0.33</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.93</P>
</TD>
<TD ALIGN="CENTER">
<P>0.05</P>
</TD>
<TD ALIGN="CENTER">
<P>-1.28</P>
</TD>
<TD ALIGN="CENTER">
<P>0.01</P>
</TD>
</TR>
<TR>
<TH>
<P>Intercept</P>
</TH>
<TD ALIGN="CENTER">
<P>101.51</P>
</TD>
<TD ALIGN="CENTER">
<P>3.81</P>
</TD>
<TD ALIGN="CENTER">
<P>26.67</P>
</TD>
<TD ALIGN="CENTER">
<P>&lt; 0.01</P>
</TD>
<TD ALIGN="CENTER">
<P>94.05</P>
</TD>
<TD ALIGN="CENTER">
<P>108.97</P>
</TD>
</TR>
<TR>
<TH>
<P>Random-effects parameters </P>
</TH>
<TH ALIGN="CENTER">
<P>Estimate</P>
</TH>
<TH ALIGN="CENTER">
<P>Standard error</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>95% confidence</P>
<P>interval</P>
</TH>
<TH COLSPAN="2" ROWSPAN="4">
<P/>
</TH>
</TR>
<TR>
<TH>
<P>SD (month)</P>
</TH>
<TD ALIGN="CENTER">
<P>2.19</P>
</TD>
<TD ALIGN="CENTER">
<P>0.16</P>
</TD>
<TD ALIGN="CENTER">
<P>1.90</P>
</TD>
<TD ALIGN="CENTER">
<P>2.52</P>
</TD>
</TR>
<TR>
<TH>
<P>SD (intercept)</P>
</TH>
<TD ALIGN="CENTER">
<P>19.61</P>
</TD>
<TD ALIGN="CENTER">
<P>0.87</P>
</TD>
<TD ALIGN="CENTER">
<P>17.98</P>
</TD>
<TD ALIGN="CENTER">
<P>21.39</P>
</TD>
</TR>
<TR>
<TH>
<P>SD (residual)</P>
</TH>
<TD ALIGN="CENTER">
<P>7.12</P>
</TD>
<TD ALIGN="CENTER">
<P>0.16</P>
</TD>
<TD ALIGN="CENTER">
<P>6.81</P>
</TD>
<TD ALIGN="CENTER">
<P>7.45</P>
</TD>
</TR>
</TABLE>
<P>In our linear mixed-effects model, the only significant fixed-effects across studies were the intercept (overall initial FVC), slope (overall change in FVC per month), and difference in intercepts (difference in overall initial FVC) between the studies. The <LINK REF="STD-Groeneveld-2003" TYPE="STUDY">Groeneveld 2003</LINK> study was made the reference group, and thus all coefficients show offsets from that study. Unexpectedly, the <LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK> study patients had statistically lower FVC values than patients in the <LINK REF="STD-Groeneveld-2003" TYPE="STUDY">Groeneveld 2003</LINK> study at enrolment (101.5 for <LINK REF="STD-Groeneveld-2003" TYPE="STUDY">Groeneveld 2003</LINK> versus 89.2 for <LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK>, P &lt; 0.01), which is reflected in Table 3A. As expected, FVC declined significantly for patients in each study (-2.12 percent/month for the combined data, P &lt; 0.01). In comparing the creatine and placebo groups, creatine actually appeared to worsen the FVC slope slightly (estimate -0.63 percent/month), but this effect was not statistically significant (P = 0.054).</P>
<P>A summary of these primary and secondary outcome findings can be found in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events from creatine</HEADING>
<P>Creatine was reportedly well-tolerated by study subjects in all three studies, with no evidence of renal failure or serious adverse events specifically attributed to creatine (see each individual paper for full details).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-11-08 09:32:04 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2012-11-08 09:31:59 +0000" MODIFIED_BY="[Empty name]">
<P>In people already diagnosed with clinically probable or definite amyotrophic lateral sclerosis (ALS), creatine at doses ranging from 5 to 10 g per day did not have a statistically significant effect on survival, ALSFRS-R progression or per cent predicted FVC progression.</P>
<P>The three included trials involved 386 participants randomized to either creatine 5 to 10 g per day or placebo. Creatine was reportedly well-tolerated in all three included studies, with no evidence of renal failure or serious adverse events specifically attributable to creatine. Using a pooled log-rank statistical test, we found no statistical difference in survival between the placebo and creatine groups across all three studies (Chi<SUP>2</SUP> = 0.09, P = 0.76). In addition, we found no statistical difference in ALSFRS-R slopes between the two groups across all three studies using a pooled linear mixed-effects model (slope difference of +0.03 ALSFRS-R/month in the creatine group; P = 0.76). Interestingly, there was a trend towards slightly worsened FVC slope in the creatine group (slope difference of -0.63 FVC/month in the creatine group) using a pooled linear mixed-effects model across the two studies which included FVC as an outcome, but this difference was not statistically significant (P = 0.054) (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-11-08 09:32:04 +0000" MODIFIED_BY="Ruth Brassington">
<P>There are several limitations to our systematic review. Firstly, every study had exclusion criteria, thus our overall conclusions may not be generalizable to ALS patients older than 75 to 80 years of age, those with FVC less than 60%, those with severely weakened upper extremities, those with ALS of more than five years' duration, or those with less clinically obvious ALS. Secondly, since there are both known and unknown variations between patients and studies, our pooled results may not be as accurate as we assumed (although we attempted to control for this variation through trial stratification and using linear mixed-effects models). Thirdly, despite our comprehensive search strategy, we may have missed a randomized creatine clinical trial (especially if its results were unpublished), thus possibly affecting the validity of our conclusions. Finally, because of the characteristics of our included studies, we cannot rule out a benefit of creatine to those very early in their disease, at higher doses, in combination with other drugs, or according to different endpoints.</P>
<P>Based on the study data available to us, we conclude that creatine alone in doses 5 to 10 g per day has no significant beneficial effect on survival, ALSFRS-R progression or FVC progression in typical ALS. There was a non-significant trend towards slightly worsened FVC progression with creatine use.</P>
</APPLICABILITY_OF_FINDINGS>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-05-11 14:26:05 +0100" MODIFIED_BY="Ruth Brassington">
<IMPLICATIONS_PRACTICE MODIFIED="2010-05-11 14:26:05 +0100" MODIFIED_BY="Ruth Brassington">
<P>Creatine in doses of 5 to 10 mg/day does not have a significant beneficial effect on survival or progression of typical ALS. While there was a hint of slightly worsened FVC progression with creatine use at these doses, this is unlikely to be clinically significant. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-03-09 22:52:29 +0000" MODIFIED_BY="[Empty name]">
<P>In typical ALS, further studies of creatine in doses of 5 to 10 g per day are unlikely to show a significant beneficial effect on survival or ALS progression. If creatine were to be researched again in the future, we would suggest starting it much earlier in the disease process (if possible) or combining it with other drugs.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-11-08 10:12:00 +0000" MODIFIED_BY="[Empty name]">
<P>We would like to thank Dr. Milan C. Mathew for his help with the initial stages of this review.</P>
<P>Editorial support from the Cochrane Neuromuscular Disease Group is funded by the Motor Neuron Disease Association and the MRC Centre for Neuromuscular Diseases.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-11-13 10:41:46 +0000" MODIFIED_BY="[Empty name]">
<P>Richard S. Bedlack was a site investigator for a multicenter trial of creatine for ALS (<LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK>). He has received consultancy fees from Athena Diagnostics, Avanir, Biogen, Sanofi and UCB and remuneration as a medical monitor for Clinipace and ultragenyx. His institution has grants pending from Biogen, Cytokinetics and Neuraltus Pharmaceuticals. He has received payment for lectures from Avanir, Eli Lilly and Pfizer and for the development of educational presentations from Athena Diagnostics. Daniel M. Pastula has no known conflicts of interest. Dan H. Moore is a biostatistical consultant for several pharmaceutical entities: Neuraltus Pharmaceuticals and Knopp Neurosciences.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-05-07 11:16:02 +0100" MODIFIED_BY="Ruth Brassington">
<P>Conceiving the review - RSB<BR/>Designing the review - RSB<BR/>Co-ordinating the review - RSB<BR/>Screening search results - DMP, RSB<BR/>Organizing retrieval of papers - RSB<BR/>Screening retrieved papers against inclusion criteria - DMP, RSB<BR/>Appraising quality of papers - DMP, RSB<BR/>Abstracting data from papers - DMP, DHM, RSB<BR/>Writing to authors of papers for additional information - RSB<BR/>Providing additional data about papers - RSB<BR/>Obtaining and screening data on unpublished studies - RSB<BR/>Data management for the review - DMP, DHM, RSB<BR/>Entering data into RevMan - DMP, RSB<BR/>Analysis of data - DMP, DHM, RSB<BR/>Interpretation of data - DMP, DHM, RSB<BR/>Writing the review - DMP, DHM, RSB<BR/>Securing funding for the review - RSB<BR/>Performing previous work that was the foundation of current study - RSB<BR/>Guarantor for the review -RSB<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-11-08 09:36:06 +0000" MODIFIED_BY="Ruth Brassington">
<P>There were a few differences between the protocol proposal (<LINK REF="REF-Bedlack-2005" TYPE="REFERENCE">Bedlack 2005</LINK>) and this actual review. Foremost, in addition to proposing examining outcomes such as survival, ALSFRS-R progression and FVC progression, the protocol also proposed to examine outcomes such as muscle strength, quality of life and costs. Unfortunately, these additional proposed outcomes were either not available in the included studies or were not practical to statistically combine. In addition, the 'Risk of bias' methodology has been updated and a 'Summary of findings' table has been added. Finally, some references have been added or updated. </P>
<P>Daniel M. Pastula joined the authors subsequent to protocol publication and Milan C Mathew withdrew.</P>
<P>At the 2012 update the wording of the 'Risk of bias' assessments was revised to "high risk of bias", "low risk of bias" or "unclear risk of bias" (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). </P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-11-13 10:40:14 +0000" MODIFIED_BY="Ruth Brassington">
<STUDIES MODIFIED="2011-09-27 15:48:19 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-09-27 15:48:19 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Groeneveld-2003" MODIFIED="2011-09-27 15:44:08 +0100" MODIFIED_BY="[Empty name]" NAME="Groeneveld 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-09-27 15:44:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, et al</AU>
<TI>A randomized sequential trial of creatine in amyotrophic lateral sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>2003</YR>
<VL>53</VL>
<NO>4</NO>
<PG>437-45</PG>
<IDENTIFIERS MODIFIED="2011-09-27 15:44:08 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-09-27 15:44:08 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="12666111"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenfeld-2008" MODIFIED="2011-09-27 15:44:59 +0100" MODIFIED_BY="[Empty name]" NAME="Rosenfeld 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-09-27 15:44:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A, et al</AU>
<TI>Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS</TI>
<SO>Amyotrophic Lateral Sclerosis</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>5</NO>
<PG>266-72</PG>
<IDENTIFIERS MODIFIED="2011-09-27 15:44:59 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-09-27 15:44:59 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="18608103"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shefner-2004" MODIFIED="2011-09-27 15:48:19 +0100" MODIFIED_BY="[Empty name]" NAME="Shefner 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-09-27 15:48:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, et al; NEALS Consortium</AU>
<TI>A clinical trial of creatine in ALS</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>9</NO>
<PG>1656-61</PG>
<IDENTIFIERS MODIFIED="2011-09-27 15:48:19 +0100" MODIFIED_BY="Angela A Gunn">
<IDENTIFIER MODIFIED="2011-09-27 15:48:19 +0100" MODIFIED_BY="Angela A Gunn" TYPE="PUBMED" VALUE="15534251"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-05-07 10:59:28 +0100" MODIFIED_BY="Ruth Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenfeld-2001" MODIFIED="2010-05-07 10:59:28 +0100" MODIFIED_BY="Ruth Brassington" NAME="Rosenfeld 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-05-07 10:59:28 +0100" MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Rosenfeld J</AU>
<TI>Creatine monohydrate in amyotrophic lateral sclerosis: preliminary results</TI>
<SO>American Academy of Neurology Annual Meeting</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-11-13 10:40:14 +0000" MODIFIED_BY="Ruth Brassington">
<ADDITIONAL_REFERENCES MODIFIED="2012-11-13 10:40:14 +0000" MODIFIED_BY="Ruth Brassington">
<REFERENCE ID="REF-Adhihetty-2008" MODIFIED="2010-01-12 10:21:20 +0000" MODIFIED_BY="Ruth Brassington" NAME="Adhihetty 2008" TYPE="JOURNAL_ARTICLE">
<AU>Adhihetty PJ, Beal MF</AU>
<TI>Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases</TI>
<SO>Neuromolecular Medicine</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>4</NO>
<PG>275-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bensimon-1994" MODIFIED="2010-05-11 14:19:27 +0100" MODIFIED_BY="Ruth Brassington" NAME="Bensimon 1994" TYPE="JOURNAL_ARTICLE">
<AU>Bensimon G, Lacomblez L, Meininger V; ALS/Riluzole Study Group</AU>
<TI>A controlled trial of riluzole in amyotrophic lateral sclerosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<NO>9</NO>
<PG>585-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bessman-1985" MODIFIED="2010-04-20 14:29:47 +0100" MODIFIED_BY="Ruth Brassington" NAME="Bessman 1985" TYPE="JOURNAL_ARTICLE">
<AU>Bessman SP, Carpenter CL</AU>
<TI>The creatine-creatine phosphate energy shuttle</TI>
<SO>Annual Review of Biochemistry</SO>
<YR>1985</YR>
<VL>54</VL>
<PG>831-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brooks-2000" MODIFIED="2010-05-09 02:36:18 +0100" MODIFIED_BY="[Empty name]" NAME="Brooks 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases</AU>
<TI>El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2000</YR>
<VL>1</VL>
<NO>5</NO>
<PG>293-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cedarbaum-1999" MODIFIED="2010-05-11 14:19:13 +0100" MODIFIED_BY="Ruth Brassington" NAME="Cedarbaum 1999" TYPE="JOURNAL_ARTICLE">
<AU>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al</AU>
<TI>The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1999</YR>
<VL>169</VL>
<NO>1-2</NO>
<PG>13-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chancellor-1993" MODIFIED="2010-05-09 02:37:37 +0100" MODIFIED_BY="[Empty name]" NAME="Chancellor 1993" TYPE="JOURNAL_ARTICLE">
<AU>Chancellor AM, Slattery JM, Fraser H, Swingler RJ, Holloway SM, Warlow CP</AU>
<TI>The prognosis of adult-onset motor neuron disease: a prospective study based on the Scottish Motor Neuron Disease Register</TI>
<SO>Journal of Neurology</SO>
<YR>1993</YR>
<VL>240</VL>
<NO>6</NO>
<PG>339-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cox-1972" MODIFIED="2010-05-09 02:38:31 +0100" MODIFIED_BY="[Empty name]" NAME="Cox 1972" TYPE="JOURNAL_ARTICLE">
<AU>Cox D</AU>
<TI>Regression models and life tables</TI>
<SO>Journal of the Royal Statistical Society. Series B (Methodological)</SO>
<YR>1972</YR>
<VL>34</VL>
<NO>2</NO>
<PG>187-220</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Czaplinski-2006" MODIFIED="2010-05-09 02:42:47 +0100" MODIFIED_BY="[Empty name]" NAME="Czaplinski 2006" TYPE="JOURNAL_ARTICLE">
<AU>Czaplinski A, Yen AA, Appel SH</AU>
<TI>Amyotrophic lateral sclerosis: early predictors of prolonged survival</TI>
<SO>Journal of Neurology</SO>
<YR>2006</YR>
<VL>253</VL>
<NO>11</NO>
<PG>1428-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Del-Aguila-2003" MODIFIED="2010-05-09 02:40:13 +0100" MODIFIED_BY="[Empty name]" NAME="Del Aguila 2003" TYPE="JOURNAL_ARTICLE">
<AU>Del Aguila M, Longstreth WT Jr, McGuire V, Koepsell T, van Belle G</AU>
<TI>Prognosis in amyotrophic lateral sclerosis: a population-based study</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>5</NO>
<PG>813-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Drory-2002" MODIFIED="2010-05-09 02:39:53 +0100" MODIFIED_BY="[Empty name]" NAME="Drory 2002" TYPE="JOURNAL_ARTICLE">
<AU>Drory VE, Gross D</AU>
<TI>No effect of creatine on respiratory distress in amyotrophic lateral sclerosis</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>1</NO>
<PG>43-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goodall-2006" MODIFIED="2010-05-09 02:40:20 +0100" MODIFIED_BY="[Empty name]" NAME="Goodall 2006" TYPE="JOURNAL_ARTICLE">
<AU>Goodall EF, Morrison KE</AU>
<TI>Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment</TI>
<SO>Expert Reviews in Molecular Medicine</SO>
<YR>2006</YR>
<VL>8</VL>
<NO>11</NO>
<PG>1-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gordon-2004" MODIFIED="2010-05-11 14:22:32 +0100" MODIFIED_BY="Ruth Brassington" NAME="Gordon 2004" TYPE="JOURNAL_ARTICLE">
<AU>Gordon PH, Miller RG, Moore DH</AU>
<TI>ALSFRS-R</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>Suppl 1</NO>
<PG>90-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-05-09 02:40:27 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]</TI>
<SO>The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-11-13 10:40:14 +0000" MODIFIED_BY="Ruth Brassington" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kleopa-1999" MODIFIED="2010-01-12 10:23:23 +0000" MODIFIED_BY="Ruth Brassington" NAME="Kleopa 1999" TYPE="JOURNAL_ARTICLE">
<AU>Kleopa KA, Sherman M, Neal B, Romano GJ, Heiman-Patterson T</AU>
<TI>Bipap improves survival and rate of pulmonary function decline in patients with ALS</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1999</YR>
<VL>164</VL>
<NO>1</NO>
<PG>82-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klivenyi-1999" MODIFIED="2010-04-20 14:44:05 +0100" MODIFIED_BY="Ruth Brassington" NAME="Klivenyi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, et al</AU>
<TI>Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis</TI>
<SO>Nature Medicine</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>3</NO>
<PG>347-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lacomblez-1996" MODIFIED="2010-05-09 02:40:53 +0100" MODIFIED_BY="[Empty name]" NAME="Lacomblez 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Powe L, Durrleman S, et al</AU>
<TI>A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group II</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>47</VL>
<NO>6 (Suppl 4)</NO>
<PG>S242-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lawler-2002" MODIFIED="2008-10-24 17:34:30 +0100" MODIFIED_BY="[Empty name]" NAME="Lawler 2002" TYPE="JOURNAL_ARTICLE">
<AU>Lawler JM, Barnes WS, Wu G, Song W, Demaree S</AU>
<TI>Direct antioxidant properties of creatine</TI>
<SO>Biochemical &amp; Biophysical Research Communications</SO>
<YR>2002</YR>
<VL>290</VL>
<NO>1</NO>
<PG>47-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-1988" MODIFIED="2010-01-12 10:24:08 +0000" MODIFIED_BY="Ruth Brassington" NAME="Li 1988" TYPE="JOURNAL_ARTICLE">
<AU>Li TM, Alberman E, Swash M</AU>
<TI>Comparison of sporadic and familial disease amongst 580 cases of motor neuron disease</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1988</YR>
<VL>51</VL>
<NO>6</NO>
<PG>778-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mandrioli-2003" MODIFIED="2010-05-11 14:22:46 +0100" MODIFIED_BY="Ruth Brassington" NAME="Mandrioli 2003" TYPE="JOURNAL_ARTICLE">
<AU>Mandrioli J, Faglioni P, Merelli E, Sola P</AU>
<TI>The epidemiology of ALS in Modena, Italy</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>4</NO>
<PG>683-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mathus_x002d_Vliegen-1994" MODIFIED="2010-04-20 14:50:08 +0100" MODIFIED_BY="Ruth Brassington" NAME="Mathus-Vliegen 1994" TYPE="JOURNAL_ARTICLE">
<AU>Mathus-Vliegen LMH, Louwerse LS, Merkus MP, Tytgat GNS, Vianney de Jong JMP</AU>
<TI>Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function</TI>
<SO>Gastrointestinal Endoscopy</SO>
<YR>1994</YR>
<VL>40</VL>
<NO>4</NO>
<PG>463-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mazzini-1995" MODIFIED="2010-04-20 14:50:36 +0100" MODIFIED_BY="Ruth Brassington" NAME="Mazzini 1995" TYPE="JOURNAL_ARTICLE">
<AU>Mazzini L, Corrà T, Zaccala M, Mora G, Del Piano M, Galante M</AU>
<TI>Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1995</YR>
<VL>242</VL>
<NO>10</NO>
<PG>695-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mazzini-2001" MODIFIED="2010-05-11 14:22:58 +0100" MODIFIED_BY="Ruth Brassington" NAME="Mazzini 2001" TYPE="JOURNAL_ARTICLE">
<AU>Mazzini L, Balzarini C, Colombo R, Moro G, Pastore I, De Ambrogio R, et al</AU>
<TI>Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2001</YR>
<VL>191</VL>
<NO>1-2</NO>
<PG>139-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meyer-1984" MODIFIED="2010-05-09 02:41:04 +0100" MODIFIED_BY="[Empty name]" NAME="Meyer 1984" TYPE="JOURNAL_ARTICLE">
<AU>Meyer RA, Sweeney HL, Kushmerick MJ</AU>
<TI>A simple analysis of the "phosphocreatine shuttle"</TI>
<SO>American Journal of Physiology</SO>
<YR>1984</YR>
<VL>246</VL>
<NO>5 Pt 1</NO>
<PG>C365-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miller-2009" MODIFIED="2010-01-12 10:24:43 +0000" MODIFIED_BY="Ruth Brassington" NAME="Miller 2009" TYPE="JOURNAL_ARTICLE">
<AU>Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al</AU>
<TI>Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology</TI>
<SO>Neurology</SO>
<YR>2009</YR>
<VL>73</VL>
<NO>15</NO>
<PG>1218-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Millul-2005" MODIFIED="2010-01-12 10:24:54 +0000" MODIFIED_BY="Ruth Brassington" NAME="Millul 2005" TYPE="JOURNAL_ARTICLE">
<AU>Millul A, Beghi E, Logroscino G, Micheli A, Vitelli E, Zardi A</AU>
<TI>Survival of patients with amyotrophic lateral sclerosis in a population-based registry</TI>
<SO>Neuroepidemiology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>3</NO>
<PG>114-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pastula-2009" MODIFIED="2010-05-09 02:41:20 +0100" MODIFIED_BY="[Empty name]" NAME="Pastula 2009" TYPE="JOURNAL_ARTICLE">
<AU>Pastula DM, Coffman CJ, Allen KD, Oddone EZ, Kasarskis EJ, Lindquist JH, et al</AU>
<TI>Factors associated with survival in the National Registry of Veterans with ALS</TI>
<SO>Amyotrophic Lateral Sclerosis</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>5-6</NO>
<PG>332-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Przedborski--2003" MODIFIED="2010-05-09 02:41:44 +0100" MODIFIED_BY="[Empty name]" NAME="Przedborski  2003" TYPE="JOURNAL_ARTICLE">
<AU>Przedborski S, Mitsumoto H, Rowland LP</AU>
<TI>Recent advances in amyotrophic lateral sclerosis research</TI>
<SO>Current Neurology and Neuroscience Reports</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>1</NO>
<PG>70-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosen-1993" MODIFIED="2010-05-11 14:23:18 +0100" MODIFIED_BY="Ruth Brassington" NAME="Rosen 1993" TYPE="JOURNAL_ARTICLE">
<AU>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al</AU>
<TI>Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis</TI>
<SO>Nature</SO>
<YR>1993</YR>
<VL>362</VL>
<NO>6415</NO>
<PG>59-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rowland-2001" MODIFIED="2008-10-24 17:35:02 +0100" MODIFIED_BY="[Empty name]" NAME="Rowland 2001" TYPE="JOURNAL_ARTICLE">
<AU>Rowland LP, Schneider NA</AU>
<TI>Amyotrophic lateral sclerosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<NO>22</NO>
<PG>1688-700</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sanofi_x002d_Aventis-2006" MODIFIED="2010-04-20 15:15:41 +0100" MODIFIED_BY="Ruth Brassington" NAME="Sanofi-Aventis 2006" TYPE="OTHER">
<AU>Sanofi-Aventis</AU>
<TI>Rilutek prescribing information</TI>
<SO>Sanofi-Aventis U.S.LLC, Bridgewater, NJ</SO>
<YR>November 2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sestili-2006" MODIFIED="2010-05-11 14:23:33 +0100" MODIFIED_BY="Ruth Brassington" NAME="Sestili 2006" TYPE="JOURNAL_ARTICLE">
<AU>Sestili P, Martinelli C, Bravi G, Piccoli G, Battistelli M, Falcieri E, et al</AU>
<TI>Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity</TI>
<SO>Free Radical Biology and Medicine</SO>
<YR>2006</YR>
<VL>40</VL>
<NO>5</NO>
<PG>837-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Siddique-1995" MODIFIED="2010-05-11 14:23:43 +0100" MODIFIED_BY="Ruth Brassington" NAME="Siddique 1995" TYPE="JOURNAL_ARTICLE">
<AU>Siddique T, Hentati A</AU>
<TI>Familial amyotrophic lateral sclerosis</TI>
<SO>Clinical Neuroscience</SO>
<YR>1995-1996</YR>
<VL>3</VL>
<NO>6</NO>
<PG>338-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sorenson-2002" MODIFIED="2010-04-20 15:09:42 +0100" MODIFIED_BY="Ruth Brassington" NAME="Sorenson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Sorenson EJ, Stalker AP, Kurland LT, Winderbank AJ</AU>
<TI>Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>2</NO>
<PG>280-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Testa-2004" MODIFIED="2010-05-09 02:43:10 +0100" MODIFIED_BY="[Empty name]" NAME="Testa 2004" TYPE="JOURNAL_ARTICLE">
<AU>Testa D, Lovati R, Ferrarini M, Salmoiraghi F, Filippini G</AU>
<TI>Survival of 793 patients with amyotrophic lateral sclerosis diagnosed over a 28-year period</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>4</NO>
<PG>208-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Traynor-2003" MODIFIED="2008-10-24 17:35:09 +0100" MODIFIED_BY="[Empty name]" NAME="Traynor 2003" TYPE="JOURNAL_ARTICLE">
<AU>Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O</AU>
<TI>Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study 1996-2000</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>2003</YR>
<VL>74</VL>
<NO>9</NO>
<PG>1258-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Traynor-2004" MODIFIED="2010-05-09 02:43:02 +0100" MODIFIED_BY="[Empty name]" NAME="Traynor 2004" TYPE="JOURNAL_ARTICLE">
<AU>Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME; NEALS Consortium</AU>
<TI>Functional outcome measures as clinical trial endpoints in ALS</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>10</NO>
<PG>1933-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Worms-2001" MODIFIED="2010-05-11 14:24:05 +0100" MODIFIED_BY="Ruth Brassington" NAME="Worms 2001" TYPE="JOURNAL_ARTICLE">
<AU>Worms PM</AU>
<TI>The epidemiology of motor neuron diseases: a review of recent studies</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2001</YR>
<VL>191</VL>
<NO>1-2</NO>
<PG>3-9</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-11-08 09:33:16 +0000" MODIFIED_BY="Ruth Brassington">
<REFERENCE ID="REF-Bedlack-2005" MODIFIED="2012-11-08 09:33:01 +0000" MODIFIED_BY="Ruth Brassington" NAME="Bedlack 2005" TYPE="COCHRANE_PROTOCOL">
<AU>Bedlack RS, Mathew MC</AU>
<TI>Creatine for amyotrophic lateral sclerosis/motor neuron disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-09-28 15:48:56 +0100" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2012-09-28 15:48:56 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD005225"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pastula-2010" MODIFIED="2012-11-08 09:33:16 +0000" MODIFIED_BY="Ruth Brassington" NAME="Pastula 2010" TYPE="COCHRANE_REVIEW">
<AU>Pastula DM, Moore DH, Bedlack RS</AU>
<TI>Creatine for amyotrophic lateral sclerosis/motor neuron disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2012-09-28 15:46:27 +0100" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2012-09-28 15:46:27 +0100" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD005225.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-05-09 02:33:53 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-05-09 02:25:18 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-05-07 11:16:14 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Groeneveld-2003">
<CHAR_METHODS MODIFIED="2010-05-07 11:16:10 +0100" MODIFIED_BY="Ruth Brassington">
<P>Randomized (1:1), double-blinded, placebo-controlled, sequential-design, multicenter trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-27 13:43:35 +0000" MODIFIED_BY="[Empty name]">
<P>175 participants with ALS were included. ALS patients over 75 years of age, with renal dysfunction, with FVC &lt; 60%, already requiring ventilation or with ALS of &gt; 5 years duration were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-27 13:07:55 +0000" MODIFIED_BY="[Empty name]">
<P>10 mg/day creatine monohydrate or placebo for a mean of 315 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-07 11:16:14 +0100" MODIFIED_BY="Ruth Brassington">
<P>Tracheostomy-free survival<BR/>ALSFRS-R<BR/>Forced vital capacity (FVC)<BR/>MVIC arm strength<BR/>SF-36 quality of life scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-05 10:34:59 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-07 11:16:58 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Rosenfeld-2008">
<CHAR_METHODS MODIFIED="2010-05-07 11:16:53 +0100" MODIFIED_BY="Ruth Brassington">
<P>Randomized (1:1), double-blinded, placebo-controlled, multicenter trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-27 13:40:05 +0000" MODIFIED_BY="[Empty name]">
<P>107 participants with ALS were included. ALS patients over 80 years of age, already requiring ventilation, with ALS of &gt; 5 years duration, with severely weakened upper extremity muscles, or with renal dysfunction were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-07 11:16:55 +0100" MODIFIED_BY="Ruth Brassington">
<P>5 g/day creatine monohydrate or placebo for 270 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-07 11:16:58 +0100" MODIFIED_BY="Ruth Brassington">
<P>Tracheostomy-free survival<BR/>ALSFRS-R<BR/>Forced vital capacity (FVC)<BR/>MVIC arm strength<BR/>Muscle fatiguability<BR/>SF-12 quality of life scores</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-05 10:35:49 +0100" MODIFIED_BY="[Empty name]">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-07 11:17:41 +0100" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Shefner-2004">
<CHAR_METHODS MODIFIED="2010-05-07 11:17:15 +0100" MODIFIED_BY="Ruth Brassington">
<P>Randomized (1:1), double-blinded, placebo-controlled, multicenter trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-07 11:17:29 +0100" MODIFIED_BY="Ruth Brassington">
<P>104 participants with ALS were included. ALS patients over 80 years of age, with an FVC &lt; 50%, already requiring ventilation, with ALS of &gt; 5 years duration or with severely weakened upper extremity muscles were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-07 11:17:32 +0100" MODIFIED_BY="Ruth Brassington">
<P>5 g/day creatine monohydrate or placebo for 180 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-27 01:30:05 +0000" MODIFIED_BY="[Empty name]">
<P>Tracheostomy-free survival<BR/>ALSFRS-R<BR/>MVIC arm strength<BR/>MVIC grip strength<BR/>Motor Unit Number Estimation (MUNE) scores<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-07 11:17:41 +0100" MODIFIED_BY="Ruth Brassington">
<P>&#8212;</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ALS = amyotrophic lateral sclerosis; ALSFRS-R = ALS functional rating revised scores; FVC = forced vital capacity; MUNE = Motor Unit Number Estimation; MVIC = maximal voluntary isometric contraction</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-05-09 02:33:53 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-05-09 02:33:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosenfeld-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-09 02:33:53 +0100" MODIFIED_BY="[Empty name]">
<P>Original participant data and study methods for this small, unpublished, pilot study were not available.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-05-09 02:25:18 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-05-07 11:17:45 +0100" MODIFIED_BY="Ruth Brassington" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-07 11:16:19 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Groeneveld-2003">
<DESCRIPTION>
<P>The randomization minimization methods of Pocock and Zelen were used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-07 11:16:59 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Rosenfeld-2008">
<DESCRIPTION>
<P>The authors claim randomization was used, but did not provide details on sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-07 11:17:45 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Shefner-2004">
<DESCRIPTION>
<P>A random number generator was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-05-07 11:17:47 +0100" MODIFIED_BY="Ruth Brassington" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-07 11:16:21 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Groeneveld-2003">
<DESCRIPTION>
<P>An independent physician outside the study assigned participants to group A or B according to the randomization minimization methods of Pocock and Zelen. An outside pharmacist prepared the trial medication and only the outside pharmacist knew the trial code.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-07 11:17:00 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Rosenfeld-2008">
<DESCRIPTION>
<P>The authors claim randomization was used, but did not provide details on allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-07 11:17:47 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Shefner-2004">
<DESCRIPTION>
<P>The authors claim randomization was used, but did not provide details on allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-05-07 11:17:58 +0100" MODIFIED_BY="Ruth Brassington" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-07 11:16:38 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Groeneveld-2003">
<DESCRIPTION>
<P>Double-blinding of both participants and investigators was used. An outside pharmacist prepared the trial medication and only the outside pharmacist knew the trial code.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-07 11:17:11 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Rosenfeld-2008">
<DESCRIPTION>
<P>Double-blinding of both participants and investigators was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-07 11:17:58 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Shefner-2004">
<DESCRIPTION>
<P>Double-blinding of both participants and investigators was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-05-09 02:25:01 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-09 02:25:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Groeneveld-2003">
<DESCRIPTION>
<P>There were no reports of missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-04-20 14:23:15 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Rosenfeld-2008">
<DESCRIPTION>
<P>Missing values for individual study visits were excluded from determinants of slope for those participants. Only actual data values were used in the analysis. There was no imputation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-05-07 11:17:53 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Shefner-2004">
<DESCRIPTION>
<P>There were no reports of missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-05-09 02:25:18 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-07 11:16:24 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Groeneveld-2003">
<DESCRIPTION>
<P>All outcomes stated in the methods section appear to have been reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-09 02:25:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rosenfeld-2008">
<DESCRIPTION>
<P>All outcomes stated in the methods section appear to have been reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-07 11:17:59 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Shefner-2004">
<DESCRIPTION>
<P>All outcomes stated in the methods section appear to have been reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-05-07 11:18:05 +0100" MODIFIED_BY="Ruth Brassington" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-07 11:16:43 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Groeneveld-2003">
<DESCRIPTION>
<P>While there are no glaring design errors, there may be other subtle sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-07 11:17:13 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Rosenfeld-2008">
<DESCRIPTION>
<P>While there are no glaring design errors, there may be other subtle sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-07 11:18:05 +0100" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Shefner-2004">
<DESCRIPTION>
<P>While there are no glaring design errors, there may be other subtle sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-11-08 09:32:33 +0000" MODIFIED_BY="Ruth Brassington">
<SOF_TABLE ID="SOF-01" MODIFIED="2012-11-08 09:32:33 +0000" MODIFIED_BY="Ruth Brassington" NO="1" READONLY="YES">
<TITLE MODIFIED="2010-04-08 11:08:51 +0100" MODIFIED_BY="Grade Profiler">Creatine for amyotrophic lateral sclerosis</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>Creatine for amyotrophic lateral sclerosis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with amyotrophic lateral sclerosis<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> creatine<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Creatine</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Tracheostomy-free survival</B>
<BR/>Follow-up: 6 to 16 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>386<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Pooled log-rank test (across all 3 studies): Chi<SUP>2</SUP> = 0.09, P = 0.76</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>ALSFRS-R slope</B>
<BR/>Change in ALSFRS-R / month<BR/>Follow-up: 6 to 16 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean ALSFRS-R slope in the intervention groups was<BR/>
<B>0.03 higher</B>
<BR/>(0.16 lower to 0.22 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>386<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Pooled linear mixed effects model (across all 3 studies): P = 0.76</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>FVC Slope</B>
<BR/>Change in FVC / month<BR/>Follow-up: 9 to 16 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean FVC slope in the intervention groups was<BR/>
<B>0.63 lower</B>
<BR/>(1.28 lower to 0.01 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>211<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Pooled linear mixed effects model (across all 3 studies): P = 0.054</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2009-12-10 15:39:32 +0000" MODIFIED_BY="Ruth Brassington"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2010-05-09 02:25:30 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-05-09 02:25:19 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASsAAAF0CAIAAAD0HojBAAAQIElEQVR42u3dv65cRRLH8SuREDhw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</FILE>
</FIGURE>
<FIGURE FILENAME="Picture1.jpg" FILE_TYPE="JPG" ID="FIG-02" MODIFIED="2010-02-27 01:32:21 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Figure 2: Kaplan Meier Curves. Survival by study (Groeneveld-Blue, Rosenfeld-Red, and Shefner-Green); solid lines are placebo and dashed lines are creatine.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Picture2.jpg" FILE_TYPE="JPG" ID="FIG-03" MODIFIED="2010-05-07 11:34:35 +0100" MODIFIED_BY="Ruth Brassington" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Figure 3. Box plot of ALSFRS-R slopes for linear fits to each patient's data. G, R and S refer to the three studies <LINK REF="STD-Groeneveld-2003" TYPE="STUDY">Groeneveld 2003</LINK>, <LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK> and <LINK REF="STD-Shefner-2004" TYPE="STUDY">Shefner 2004</LINK>; 0 refers to placebo controls and 1 refers to creatine treated. Each box shows the middle 50% of the slopes and the horizontal line in each box shows the median slope. Small dots are outlier observations, defined as those more than 1.5 inter-quartile ranges away from the quartile boundaries. The horizontal red line is at a slope of -1.0 ALSFRS-R units per month, and is provided for reference.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Picture3.jpg" FILE_TYPE="JPG" ID="FIG-04" MODIFIED="2010-05-09 02:25:30 +0100" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Figure 4. Box plot of FVC slopes for linear fits to each patient's data. G and R refer to the two studies <LINK REF="STD-Groeneveld-2003" TYPE="STUDY">Groeneveld 2003</LINK> and <LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK>; 0 refers to placebo and 1 refers to creatine treated. Each box shows the middle 50% of the slopes and the horizontal line in each box shows the median slope. Small dots are outlier observations, defined as those more than 1.5 inter-quartile ranges away from the quartile boundaries. The horizontal red line is at a slope of -2 FVC % per month, and is provided for reference.</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-11-08 09:38:40 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-11-08 09:38:32 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-11-08 09:38:32 +0000" MODIFIED_BY="Angela Gunn">MEDLINE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-16 14:08:50 +0100" MODIFIED_BY="[Empty name]">
<P>Database: Ovid MEDLINE(R) &lt;1946 to July Week 1 2012&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 randomized controlled trial.pt. (331546)<BR/>2 controlled clinical trial.pt. (84599)<BR/>3 randomized.ab. (234978)<BR/>4 placebo.ab. (132769)<BR/>5 drug therapy.fs. (1549547)<BR/>6 randomly.ab. (169285)<BR/>7 trial.ab. (243449)<BR/>8 groups.ab. (1111291)<BR/>9 or/1-8 (2879437)<BR/>10 exp animals/ not humans.sh. (3752922)<BR/>11 9 not 10 (2445408)<BR/>12 exp Motor Neuron Disease/ (17536)<BR/>13 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease$1).mp. (5856)<BR/>14 ((Lou Gehrig$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 disease)).mp. (65)<BR/>15 charcot disease.tw. (11)<BR/>16 Amyotrophic Lateral Sclerosis.mp. (14213)<BR/>17 or/12-16 (21155)<BR/>18 creatine/ (7560)<BR/>19 creatine.mp. (41486)<BR/>20 18 or 19 (41486)<BR/>21 11 and 17 and 20 (71)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-11-08 09:38:40 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-11-08 09:38:40 +0000" MODIFIED_BY="Angela Gunn">EMBASE (OvidSP) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-16 14:09:21 +0100" MODIFIED_BY="[Empty name]">
<P>Database: Embase &lt;1980 to 2012 Week 28&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 crossover-procedure/ (34368)<BR/>2 double-blind procedure/ (109663)<BR/>3 randomized controlled trial/ (324959)<BR/>4 single-blind procedure/ (16095)<BR/>5 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind$) or (singl$ adj blind$) or assign$ or allocat$ or volunteer$).tw. (1136980)<BR/>6 or/1-5 (1214775)<BR/>7 exp animals/ (1779961)<BR/>8 exp humans/ (13608562)<BR/>9 7 not (7 and 8) (1331293)<BR/>10 6 not 9 (1174131)<BR/>11 limit 10 to embase (927003)<BR/>12 motor neuron disease/ or amyotrophic lateral sclerosis/ (22966)<BR/>13 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease$1).mp. (8509)<BR/>14 ((Lou Gehrig$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 disease)).mp. (107)<BR/>15 charcot disease.tw. (18)<BR/>16 amyotrophic lateral sclerosis.tw. (14138)<BR/>17 or/12-16 (25559)<BR/>18 creatine/ (9646)<BR/>19 creatine.tw. (32815)<BR/>20 18 or 19 (36992)<BR/>21 11 and 17 and 20 (35)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-09-27 15:52:28 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-12-17 17:59:15 +0000" MODIFIED_BY="Angela Gunn">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-09-27 15:52:28 +0100" MODIFIED_BY="[Empty name]">
<P>#1 MeSH descriptor Motor Neuron Disease explode all trees<BR/>#2 "motor neuron disease" or "motor neurone disease" or "motoneuron disease" or "amyotrophic lateral sclerosis"<BR/>#3 Charcot NEXT disease<BR/>#4 Lou NEXT Gehrig NEAR syndrome<BR/>#5 Lou NEXT Gehrig NEAR disease<BR/>#6 (#1 OR #2 OR #3 OR #4 OR #5)<BR/>#7 MeSH descriptor Creatine, this term only<BR/>#8 creatin*<BR/>#9 (#7 OR #8)<BR/>#10 (#6 AND #9)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>